SLC5A2 and chronic kidney disease: Since the workshop, the CREDENCE trial using SGLT2 inhibitors, a post-hoc study of the EMPA-REG OUTCOME trial, a prespecified analysis of the DAPA-CKD trial, and a post-hoc study of the LEADER trial on GLP-1 analogs have been reported.